EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. In addition, the company has developed DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. Further, it develops YUTIQ shorter-actinguveitis for the treatment of posterior segment uveitis; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Additionally, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It sells its products primarily in the United States and Europe. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, and Enigma Therapeutics Limited. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Phone617-926-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.96 million
Profitability
Miscellaneous
Employees44
OptionableOptionable
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions
What is Eyepoint Pharmaceuticals' stock symbol?
Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."
How were Eyepoint Pharmaceuticals' earnings last quarter?
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) announced its earnings results on Tuesday, November, 6th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The business earned $0.49 million during the quarter, compared to analysts' expectations of $0.70 million. Eyepoint Pharmaceuticals had a negative net margin of 2,622.93% and a negative return on equity of 193.49%. View Eyepoint Pharmaceuticals' Earnings History.
When is Eyepoint Pharmaceuticals' next earnings date?
What price target have analysts set for EYPT?
2 analysts have issued 12 month price objectives for Eyepoint Pharmaceuticals' stock. Their predictions range from $5.00 to $6.00. On average, they expect Eyepoint Pharmaceuticals' stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 143.4% from the stock's current price. View Analyst Price Targets for Eyepoint Pharmaceuticals.
What is the consensus analysts' recommendation for Eyepoint Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyepoint Pharmaceuticals.
What are Wall Street analysts saying about Eyepoint Pharmaceuticals stock?
Here are some recent quotes from research analysts about Eyepoint Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA. " (11/13/2018)
- 2. HC Wainwright analysts commented, "We’d like to remind investors that EyePoint Pharmaceuticals has major regulatory and commercial milestones in the near term. Specifically, YUTIQ three-year treatment of posterior uveitis has a PDUFA date of and DEXYCU for post-operative ocular inflammation is slated to be commercially launched in 1H19. If YUTIQ secures FDA approval in the coming month, it would also be launched in 1H19. The company has entered into an agreement with a contract sales organization to ensure a fully trained and seasoned field organization at product launch. In our view, DEXYCU has attractive market prospects as it would be the first FDA-approved drop-less product on the ocular surgery market that allows patients to do away with conventional eye drops used to control inflammation after the surgery." (10/1/2018)
Has Eyepoint Pharmaceuticals been receiving favorable news coverage?
News headlines about EYPT stock have trended extremely positive on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eyepoint Pharmaceuticals earned a media sentiment score of 4.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
Who are some of Eyepoint Pharmaceuticals' key competitors?
Some companies that are related to Eyepoint Pharmaceuticals include Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Scientific Industries (SCND), Pressure Biosciences (PBIO), Bio-Rad Laboratories (BIO.B) and PositiveID (PSID).
Who are Eyepoint Pharmaceuticals' key executives?
Eyepoint Pharmaceuticals' management team includes the folowing people:
- Ms. Nancy S. Lurker, Pres, CEO & Director (Age 61)
- Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 68)
- Dr. Dario A. Paggiarino, VP & Chief Medical Officer (Age 61)
- Mr. David J. Price, Chief Financial Officer (Age 55)
- Mr. Marty Nazzaro, Sr. VP of Operations
Who are Eyepoint Pharmaceuticals' major shareholders?
Eyepoint Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.02%). Company insiders that own Eyepoint Pharmaceuticals stock include Ew Healthcare Partners, LP and Nancy Lurker. View Institutional Ownership Trends for Eyepoint Pharmaceuticals.
Which institutional investors are buying Eyepoint Pharmaceuticals stock?
EYPT stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Ew Healthcare Partners, LP and Nancy Lurker. View Insider Buying and Selling for Eyepoint Pharmaceuticals.
How do I buy shares of Eyepoint Pharmaceuticals?
Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eyepoint Pharmaceuticals' stock price today?
One share of EYPT stock can currently be purchased for approximately $2.26.
How big of a company is Eyepoint Pharmaceuticals?
Eyepoint Pharmaceuticals has a market capitalization of $214.37 million and generates $2.96 million in revenue each year. The company earns $-53,170,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Eyepoint Pharmaceuticals employs 44 workers across the globe.
What is Eyepoint Pharmaceuticals' official website?
How can I contact Eyepoint Pharmaceuticals?
Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]
MarketBeat Community Rating for Eyepoint Pharmaceuticals (NASDAQ EYPT)
MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
